Millennium Management’s CRISPR Therapeutics CRSP Stock Holding History

Millennium Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.15M	Buy	+57,700	New	+$3.04M	﹤0.01%	3421
2024 Q4	–	Sell	-33,000	Closed	-$1.55M	–	6030
2024 Q3	$1.55M	Buy	+33,000	New	+$1.67M	﹤0.01%	3932
2024 Q2	–	Sell	-3,100	Closed	-$211K	–	5980
2024 Q1	$211K	Buy	+3,100	New	+$222K	﹤0.01%	5346
2023 Q3	–	Sell	-50,500	Closed	-$2.84M	–	6187
2023 Q2	$2.84M	Buy	50,500 +20,500	+68%	+$1.16M	﹤0.01%	3180
2023 Q1	$1.36M	Buy	+30,000	New	+$1.46M	﹤0.01%	3803
2022 Q3	–	Sell	-20,000	Closed	-$1.22M	–	7125
2022 Q2	$1.22M	Sell	20,000 -1,400	-7%	-$82.3K	﹤0.01%	4201
2022 Q1	$1.34M	Sell	21,400 -6,100	-22%	-$383K	﹤0.01%	4248
2021 Q4	$2.08M	Sell	27,500 -2,500	-8%	-$218K	﹤0.01%	3743
2021 Q3	$3.36M	Buy	30,000 +5,100	+20%	+$641K	﹤0.01%	3333
2021 Q2	$4.03M	Buy	24,900 +2,400	+11%	+$292K	﹤0.01%	3046
2021 Q1	$2.74M	Sell	22,500 -17,500	-44%	-$2.64M	﹤0.01%	3224
2020 Q4	$6.12M	Buy	+40,000	New	+$4.73M	﹤0.01%	2245
2020 Q3	–	Sell	-25,000	Closed	-$1.84M	–	4503
2020 Q2	$1.84M	Buy	+25,000	New	+$1.46M	﹤0.01%	2600

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management's CRSP Position: Q2 2026 in Review

Millennium Management increased its CRISPR Therapeutics (CRSP) stake by 1.3% in Q2 2026, buying an estimated $256K and bringing the position to 382,032 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #1587.

Millennium Management first reported a position in CRSP in Q4 2016 and has held it in 30 quarters since. The position peaked at $29.2M in Q4 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Millennium Management held 382,032 shares of CRISPR Therapeutics worth $20.8M as of Q2 2026.
Millennium Management bought 4,854 CRISPR Therapeutics shares in Q2 2026, an estimated $256K.
CRISPR Therapeutics made up 0.01% of Millennium Management's portfolio in Q2 2026, its #1587 holding.
Millennium Management first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 30 quarters since.
Millennium Management's CRISPR Therapeutics position peaked at $29.2M in Q4 2021.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.